Early-Start Antiplatelet Treatment After Neurosurgery in Patients With Spontaneous Intracerebral Hemorrhage

Spontaneous Intracerebral Hemorrhage Clinical Trial

Official title: Early-Start Antiplatelet Treatment After Neurosurgery in Patients With Spontaneous Intracerebral Hemorrhage

Status Recruiting

Clinical Trial Summary

This study is a multicenter, prospective, open-label, endpoint-blind, randomized controlled study.Patients receiving surgical treatment for SICH were divided into groups using the random machine method. In addition to conventional treatment for spontaneous intracerebral hemorrhage, patients in the group of early initiation of antiplatelet therapy were given conventional dose of aspirin (100mg, qd) antiplatelet therapy starting from the 3rd day after surgery.An independent group of investigators evaluated cardiac, cerebral and peripheral vascular events and bleeding events at four different time points.To evaluate the benefits and safety of early postoperative initiation of antiplatelet therapy in patients with spontaneous intracerebral hemorrhage.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Cerebral Hemorrhage
• Hemorrhage
• Spontaneous Intracerebral Hemorrhage

• NCT number: NCT04820972
• Study type: Interventional
• Source: Beijing Tiantan Hospital
• Contact: JUN WU, MD
• Phone: +8613426322945
• Email: wujunslf@126.com
• Status: Recruiting
• Phase: N/A
• Start date: May 1, 2021
• Completion date: May 2023